Brought to you by 
Nippon Shinyaku gets Japanese Vidaza rights from Pharmion
04 Dec 2006
Executive Summary
Nippon Shinyaku has licensed exclusive rights to develop and commercialize Pharmion's (cancer and hematology therapeutics) anticancer drug Vidaza (azacitidine for injectable suspension) in Japan.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Nippon Shinyaku gets Japanese Vidaza rights from Pharmion
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice